Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4: ...

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York. A live webcast of the presentation will be available h ...

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today annou ...

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today anno ...

Financial Data and Key Metrics Changes - The company reported a cash, cash equivalents, and marketable securities balance of $541.5 million as of March 31, 2024, with a projected runway into 2027 based on strong operational execution and financial discipline [10][22][23] - Research and development expenses increased in Q1 2024 compared to Q1 2023, primarily due to higher external spending related to clinical trials [22] Business Line Data and Key Metrics Changes - The Bemnifosbuvir program for COVID-19 is progressing with a completed enrollment of 2,221 patients in the SUNRISE-3 Phase 3 trial, focusing on high-risk patients [6][18] - The Phase 2 program for hepatitis C (HCV) reported a 98% sustained virologic response (SVR4) rate from the leading cohort of 60 patients, with plans to present new efficacy data at the upcoming EASL conference [8][12][15] Market Data and Key Metrics Changes - The U.S. HCV market demand grew approximately 5% in 2023, with over 2 million individuals estimated to be infected, indicating a significant patient pool for treatment [12] - The market opportunity for oral antiviral therapeutics for COVID-19 is projected to remain a multibillion-dollar opportunity, with annual revenues estimated between $4 billion and $5 billion for the two approved oral antiviral products [21] Company Strategy and Development Direction - The company aims to address unmet medical needs in COVID-19 and HCV treatment through innovative therapies, with a focus on the combination of Bemnifosbuvir and ruzasvir for HCV [11][17] - The company plans to initiate a Phase 3 study for HCV around the end of 2024, following the completion of the current Phase 2 study [9][26] Management's Comments on Operating Environment and Future Outlook - Management highlighted the ongoing evolution of COVID-19 variants and the need for effective treatments, emphasizing the potential of Bemnifosbuvir to meet this demand [6][16] - The company expressed optimism about upcoming data presentations and the potential for significant shareholder value driven by key milestones in both COVID-19 and HCV programs [24][26] Other Important Information - The company is preparing for a Phase 3 study for HCV, with a focus on a fixed-dose combination tablet that aims to minimize pill burden [9][48] - Management indicated that the current cash runway includes plans for potential partnerships in the COVID-19 program while also engaging in initial commercialization activities [58] Q&A Session Summary Question: What percentage of the 220 patients in the HCV trial will be rolling patients? - The target is to enroll at least 10% to 20% of the 220 patients [30] Question: What is the pathway for registration for the HCV trial? - The company anticipates needing two Phase 3 trials, likely one against a comparator, and plans to execute the Phase 3 program independently [32][41] Question: Thoughts on Shionogi's recent Phase 3 update? - Management noted the importance of focusing on hospitalization as a primary endpoint, contrasting it with Shionogi's approach [36] Question: Will the EASL data include long-term SVR results? - New Phase 2 efficacy data will be presented, but specifics on SVR12 cannot be disclosed due to embargo [40] Question: How large of a safety database is needed for registration? - A safety database of around 1,000 patients is typically required for a combination antiviral like this [55]

First Quarter Results and Business Update May 14, 2024 NASDAQ: AVIR June 2020 DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Ef icacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, Mass., May ...

BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference call, participant ...

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024 (ESCMID, formerly ECCMID), which is taking place April ...